Abstract
Introduction
Lipoprotein(a) [Lp(a)] is associated with ischemic stroke, but the strength of association based on demographic differences remains unclear. We aimed to investigate the association between Lp(a)>125 nmol/L and stroke by age, sex, and racial/ethnic subgroups.
Methods
Using data from the UK Biobank, we included 353,309 participants with an Lp(a) measurement without a history of atherosclerotic cardiovascular disease (ASCVD). Stroke was defined as ischemic stroke or hemorrhagic stroke (with subtypes subarachnoid hemorrhage and intracerebral hemorrhage). Cox proportional hazards models were used to evaluate the association between elevated Lp(a) and stroke (ischemic or hemorrhagic), adjusted for ASCVD risk factors, race/ethnicity, lipid lowering therapy, antiplatelet and anticoagulation medications. Outcomes were defined using ICD-10 codes.
Results
The study population consisted of 55.7 % women and 94 % White individuals with average age of 56 years. The median Lp(a) level was 20.9 [IQR 9.5, 61.4] nmol/L and prevalence of Lp(a) >125 nmol/L was 11.1 % (n = 39,067). Over a median follow-up of 13.8 [13.1, 14.5] years, there were 5002 (1.4 %) ischemic strokes and 1462 (0.4 %) hemorrhagic strokes. Lp(a) > 125 nmol/L was associated with increased risk for ischemic stroke (HR 1.12, 95 % CI 1.02–1.22, P = 0.019), but not hemorrhagic stroke (HR 0.95, 95 % CI 0.79–1.13, P = 0.545). The association between Lp(a)>125 nmol/L and ischemic stroke did not vary by age (p-interaction=0.691) or race/ethnicity (p-interaction 0.526) but did vary by sex (p-interaction=0.041) with an association among men (HR 1.20, 95 % CI 1.07–1.36) but not among women.
Conclusion
Lp(a) is independently associated with ischemic stroke, with variation by sex but not age or race/ethnicity. Lp(a) was not significantly associated with hemorrhagic stroke.
Keywords: Lipoprotein(a), Stroke, Prevention, Risk factors
1. Introduction
Lipoprotein(a) [Lp(a)] is an established risk factor for ischemic stroke, though not as strongly as for coronary artery disease [1,2]. As a primarily inheritable lipoprotein, Lp(a) is approximately six-fold more atherogenic than LDL-C on an equimolar basis [3]. The ACC/AHA guidelines consider Lp(a) above 50 mg/dL or approximately 125 nmol/L as a risk enhancer for atherosclerotic cardiovascular disease (ASCVD) [4]. At this level, approximately 20 % of the population has an elevated Lp(a). Multiple professional societies have recommended universal Lp(a) screening in adults for risk stratification [5]; however, testing rates remain low[6].
Clinical and Mendelian randomization studies have shown a potentially causal relationship between elevated Lp(a) and ischemic stroke [[7], [8], [9], [10], [11], [12]]. In the Atherosclerosis Risk in Communities (ARIC) study of 14,221 middle-aged individuals without clinical cardiovascular diseases, risk of ischemic stroke was higher than coronary heart disease among individuals with Lp(a) >30 mg/dL [13,14]. The association between Lp(a) and hemorrhagic stroke is less clear. Given evidence for anti-fibrinolytic and potentially pro-aggregatory platelet effects of Lp(a), it has been proposed that elevated Lp(a) may be associated with decreased bleeding risk [15]; however, studies of hemorrhagic stroke risk in association with Lp(a) have been inconsistent with some suggesting increased risk of hemorrhagic stroke [16,17] and others suggesting reduced risk of intracerebral hemorrhage [18].
While Lp(a) is associated with increased risk for ischemic stroke, the association by demographic differences remain unclear, with prior studies producing conflicting results, particularly related to race/ethnicity and sex [[9], [10], [11], [12], [13],19]. In this study, we evaluated the association of Lp(a) with ischemic and hemorrhagic stroke in individuals without prior known ASCVD, stratified by age, sex and race/ethnicity.
2. Methods
2.1. Study population and characterization
This study was conducted using data from the UK Biobank. The UK Biobank is a large, prospective cohort study of 502,424 participants aged 40–69 years recruited between 2006 and 2010 across 22 sites of the United Kingdom [20]. Participants were characterized by detailed questionnaires, biochemical assays, accelerometry, multi-modal imaging, genome-wide genotype during enrollment and longitudinal follow up. Race/ethnicity was determined by self-report [21]. Data analysis was performed under application number 100,584.
Serum Lp(a) was measured in nmol/L at enrollment with an immunoturbidimetric bioassay (Randox Bioscience, UK). This bioassay minimizes Lp(a) isoform heterogeneity, and the analytical range was 3.8 to 189 nmol/L[22].
Outcomes were defined by International Classification of Diseases-10 codes. For this study, ischemic stroke (I63) and hemorrhagic stroke (with subtypes subarachnoid hemorrhage (I60) and intracerebral hemorrhage(I61)) were evaluated.
2.2. Statistical analysis
Individuals who withdrew consent (n = 233), without Lp(a) measurement (n = 126,792), with history of prior ASCVD event (n = 21,792), and with both incident ischemic and hemorrhagic strokes (n = 298) were excluded. A total of 353,309 were included in the analysis. Baseline characteristics between those with available Lp(a) data and those with missing data were compared, and no clinically meaningful differences were noted. Baseline characteristics of participants included in the study were stratified by Lp(a) level of 125 nmol/L. Continuous variables were compared with ANOVA or Kruskal-Wallis testing, as appropriate, and categorical variables were compared with Chi-Square tests.
Cox proportional hazards regression was used to evaluate the association between elevated Lp(a), defined as >125 nmol/L, and stroke types. Models were adjusted for traditional ASCVD risk factors (age, sex, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), systolic blood pressure, diabetes mellitus, current smoking), and use of medications that may affect stroke risk (anti-hypertensive, lipid-lowering, anti-platelet, and anti-coagulant therapy). Evaluation of the association between a continuous measure of Lp(a), per standard deviation, and outcomes was also conducted. The proportional hazards assumption was satisfied.
Stratified analyses were conducted by age group (≤55, 55–65, >65 years), sex, and race/ethnicity (White, South Asian, Black) using similar regression models as above. Age groups were chosen based on prior studies[19,23], and the consideration of events at age ≤55 as premature. Multiplicative interaction testing was conducted between elevated Lp(a) and age, sex, and race/ethnicity in similar models as above. All analyses were performed using R (version 4.3.1). A two-tailed p-value <0.05 was considered statistically significant.
3. Results
Baseline characteristics of participants stratified by Lp(a) level are shown in Table 1. The study population consisted of 55.7 % women; 94 % of individuals were White, 2.1 % South Asian, 1.6 % Black, and 0.4 % Chinese. The average age was 56.2 (8.1) years with median follow-up of 13.8 [13.1, 14.5] years. The median Lp(a) level was 20.9 [IQR 9.5, 61.4] nmol/L and prevalence of Lp(a) >125 nmol/L was 11.1 % (n = 39,067). Individuals with Lp(a) >125 nmol/L were more likely to be women, of Black race/ethnicity, and to be on lipid lowering and anti-platelet therapy.
Table 1.
Baseline characteristics by Lp(a) level.
| Overall (n = 353,309) |
Lp(a) ≤125 nmol/L (n = 314,242) | Lp(a) >125 nmol/L (n = 39,067) | p | |
|---|---|---|---|---|
| Age, years | 56.18 (8.10) | 56.15 (8.11) | 56.39 (8.01) | <0.001 |
| Female | 196,737 (55.7) | 174,308 (55.5) | 22,429 (57.4) | <0.001 |
| Race / ethnicity | <0.001 | |||
| White | 331,599 (93.9) | 294,852 (93.8) | 36,747 (94.1) | |
| South Asian | 7323 (2.1) | 6765 (2.2) | 558 (1.4) | |
| Black | 5822 (1.6) | 4818 (1.5) | 1004 (2.6) | |
| Chinese | 1266 (0.4) | 1216 (0.4) | 50 (0.1) | |
| Other | 7299 (2.1) | 6591 (2.1) | 708 (1.8) | |
| Hypertension | 88,008 (24.9) | 78,031 (24.8) | 9977 (25.5) | 0.002 |
| Diabetes | 15,131 (4.3) | 13,551 (4.3) | 1580 (4.0) | 0.014 |
| Current smoking | 36,498 (10.3) | 32,438 (10.3) | 4060 (10.4) | 0.676 |
| Hypertension medication use | 31,145 (8.8) | 27,796 (8.8) | 3349 (8.6) | 0.074 |
| Lipid lowering therapy | 25,668 (7.3) | 22,507 (7.2) | 3161 (8.1) | <0.001 |
| Anti-platelet medication | 34,897 (9.9) | 30,900 (9.8) | 3997 (10.2) | 0.013 |
| Oral anti-coagulant medication | 2574 (0.7) | 2284 (0.7) | 290 (0.7) | 0.758 |
| Systolic blood pressure, mmHg | 139.49 (19.63) | 139.43 (19.63) | 139.96 (19.59) | <0.001 |
| Total cholesterol, mmol/L | 5.75 (1.11) | 5.73 (1.11) | 5.92 (1.10) | <0.001 |
| High density lipoprotein cholesterol, mmol/L | 1.46 (0.38) | 1.45 (0.38) | 1.49 (0.38) | <0.001 |
| Low density lipoprotein cholesterol, mmol/L | 3.60 (0.84) | 3.58 (0.84) | 3.74 (0.84) | <0.001 |
| Lp(a), nmol/L | 20.90 [9.53, 61.40] | 17.14 [8.78, 42.40] | 154.50 [139.30, 171.84] | <0.001 |
| Follow-up time, years | 13.8 [13.1, 14.5] | 13.8 [13.1, 14.5] | 13.8 [13.1, 14.5] | 0.974 |
Data are presented as n(%), mean(SD) or median[IQR].
Among 353,309 participants without a prior ASCVD event, there were 5002 (1.4 %) ischemic strokes and 1462 (0.4 %) hemorrhagic strokes (634, 0.2 % subarachnoid hemorrhage and 938, 0.3 % intracerebral hemorrhage) over a median 13.8 [13.1, 14.5] years of follow-up. The overall rate of ischemic stroke was 0.11 % per year. There was a higher incidence of ischemic stroke among those with Lp(a) >125 nmol/L, but not hemorrhagic stroke or its subtypes (Supplemental Table 1). Lp(a) >125 nmol/L was associated with a 12 % increased risk for ischemic stroke (HR 1.12, 95 % CI 1.02–1.22, p = 0.019), but not hemorrhagic stroke (HR 0.95, 95 % CI 0.79–1.13, P = 0.544), subarachnoid hemorrhage (HR 0.96, 95 % CI 0.73–1.26, p = 0.770) or intracerebral hemorrhage (HR 0.92, 95 % CI 0.73–1.16, p = 0.482) (Fig. 1). Similarly, each standard deviation increment in Lp(a) was associated with a higher risk for ischemic stroke (HR=1.03, 95 % CI: 1.01–1.06, p = 0.048), but not other evaluated outcomes (Supplemental Table 2).
Fig. 1.
Association of Lp(a) >125 nmol/L with stroke.
Subarachnoid and intracerebral hemorrhage are subtypes of hemorrhagic stroke. Adjusted for age, sex, total cholesterol, HDL-C, systolic blood pressure, diabetes mellitus, current smoking, and anti-hypertensive, cholesterol lowering and anti-platelet and anti-coagulant medication.
When stratified by age, there was no difference in the association between Lp(a) >125 nmol/L and ischemic stroke by age group (p-interaction 0.691, Fig. 2). Similar results were observed when Lp(a) was evaluated continuously (Supplemental Table 3). When evaluated by sex, 2947 (1.8 %) men and 2055 (1.0 %) women had an ischemic stroke. The median age of stroke onset was 70.8 [65.8, 75.2] in women and 70.0 [64.3, 74.3] in men. A significant association between Lp(a) >125 nmol/L and ischemic stroke was seen among men (HR 1.20, 95 % CI 1.07–1.36, P = 0.002), but not women (HR 0.99, 95 % CI 0.86–1.15, p = 0.935, p for interaction=0.041, Fig. 2). Similar results were observed when Lp(a) was evaluated continuously (Supplemental Table 4). When stratified by race/ethnicity, there was no difference in the association between Lp(a) >125 nmol/L and ischemic stroke by racial/ethnic group (p-interaction 0.526, Fig. 2)
Fig. 2.
Association of Lp(a) >125 nmol/L with Ischemic stroke by demographics.
Adjusted for age, sex, total cholesterol, HDL-C, systolic blood pressure, diabetes mellitus, current smoking, and anti-hypertensive, cholesterol lowering and anti-platelet and anti-coagulant medication.
4. Discussion
Among more than 350,000 participants without prior ASCVD from the UK Biobank, elevated Lp(a) was modestly associated with an increased risk for ischemic stroke. The association between Lp(a) >125 nmol/L and ischemic stroke was stronger among men than women, without a difference by age or race/ethnicity. We did not identify an association between Lp(a) >125 nmol/L and hemorrhagic stroke or its subtypes of subarachnoid and intracerebral hemorrhage.
Prior studies have evaluated the association between Lp(a) and ischemic stroke by age, sex and race/ethnicity. In a meta-analysis of 90,904 participants of studies evaluating ischemic stroke, greater risk was observed in individuals <55 years of age with higher Lp(a) levels compared with older individuals; sex-specific associations were inconsistent [10]. In an analysis of the prospective, multicenter BIOSIGNAL study, Lp(a) ≥100 nmol/L was independently associated with large artery atherosclerotic stroke, particularly among individuals <60 years of age with a significant interaction by age [12]. In the REGARDS study, higher Lp(a) quartile was more strongly associated with ischemic stroke among Black compared with White individuals with similar associations by sex[9]. In the ARIC study, the association between Lp(a) per 10 mg/dL or 25 nmol/L increment and ischemic stroke was numerically stronger among Black compared with White individuals, with similar associations by sex [9,11,13]. Another analysis from ARIC demonstrated an association between Lp(a) ≥30 mg/dL, or approximately 75 nmol/L, and ischemic stroke in Black individuals and in white women, but not in white men [13]. A study of nearly 6000 individuals >65 years of age observed a threefold increase in ischemic stroke risk among men, but not in women, in the highest quintile of Lp(a) (up to 47.5 mg/dL)[19,23].
Our study adds to this literature by evaluating demographic differences in a modern cohort with extended follow-up and a very large sample size. Regarding age, while prior studies have observed a differential association in Lp(a) and ischemic stroke risk by age, we did not observe such a difference. Overall, the impact of Lp(a) on an individual’s stroke risk was modest, especially for young, healthy adults. We did demonstrate a stronger association between elevated Lp(a) and ischemic stroke in men than in women. These results should be interpreted with caution as the overall rate of stroke in women was low, and further study is needed. Finally, we did not observe a variation in the association of Lp(a) with ischemic stroke by race/ethnicity, while prior studies have inconsistently demonstrated variation by race/ethnicity. These collective findings, particularly the lack of difference by age or race/ethnicity, emphasize the importance of broad Lp(a) measurement to identify risk or a potential underlying cause for ischemic stroke.
Our study has limitations. First, outcomes were defined by ICD-10 codes which may be subject to misclassification. Additionally, we were unable to reliably evaluate subtypes of ischemic stroke due to the infrequent use of these ICD-10 codes in the UK. Second, our findings may be subject to selection bias as UK Biobank participants were relatively healthy and may not be representative of the general population; this may be reflected in the fact that there was a lower prevalence of elevated Lp(a) in this population than the general population. Prior studies of this population have reported similar Lp(a) levels[22]. Third, though absolute numbers of individuals of racial/ethnic minority groups were large, the predominance of individuals in the UK Biobank were White, and further studies are needed to evaluate racial/ethnic differences in the association between Lp(a) and ischemic stroke in large, multi-ethnic populations. Finally, Lp(a) may be an important risk factor for recurrent stroke; however, we were unable to assess the association of Lp(a) and recurrent ischemic stroke due to limited events.
5. Conclusions
Lp(a) is a modest, independent risk factor for ischemic stroke, particularly among men, without significant variation by age or race/ethnicity. In contrast, Lp(a) was not significantly associated with hemorrhagic stroke, subarachnoid hemorrhage, or intracerebral hemorrhage. Measurement of Lp(a) should be incorporated into assessment for stroke risk and to evaluate for underlying cause of ischemic stroke.
Author agreement
This is to certify that all authors have seen and approved the final version of the manuscript being submitted. The article is of original work, hasn't received prior publication and isn't under consideration for publication elsewhere.
Funding
Dr. Bhatia is supported by National Institutes of Health, Grant 1K08HL166962. Dr. Razavi is supported by the National Heart, Lung, and Blood Institute, Grant F32HL172499. Dr. Tsimikas is supported by NHLBI grants R01 HL159156 and HL170224. Dr. Saeed has no financial disclosures relevant to this manuscript but she receives grant funding from the American Heart Association on investigating the Heart-Brain axis (23CDA1055489). Dr. Longstreth receives support from NIH on several projects.
CRediT authorship contribution statement
Andrew S. Kao: Writing – review & editing, Investigation, Conceptualization, Writing – original draft. Jonathan Kermanshahchi: Writing – review & editing, Writing – original draft. Shamim Khosrowjerdi: Writing – review & editing, Writing – original draft. Alexander C. Razavi: Validation, Conceptualization, Writing – review & editing. Jacqueline Levene: Writing – review & editing. Mikaila Reyes: Writing – review & editing. Parveen Garg: Conceptualization, Writing – review & editing. W.T. Longstreth: Conceptualization, Writing – review & editing. Kristiina Rannikmae: Conceptualization, Validation. Cathie Sudlow: Conceptualization, Validation. Michael Tsai: Conceptualization, Writing – review & editing. Sotirios Tsimikas: Conceptualization, Validation, Supervision, Writing – review & editing. Anum Saeed: Conceptualization, Writing – review & editing, Validation. Harpreet S. Bhatia: Validation, Data curation, Investigation, Writing – review & editing, Formal analysis, Supervision, Conceptualization.
Declaration of competing interest
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:
Dr. Harpreet Bhatia reports a relationship with National Institutes of Health that includes: funding grants. Dr. Alexander C. Razavi reports a relationship with National Heart Lung and Blood Institute that includes: funding grants. Dr. Sotirios Tsimikas reports a relationship with National Heart Lung and Blood Institute that includes: funding grants. Dr. Anum Saeed reports a relationship with American Heart Association Inc that includes: funding grants. Dr. Will Longstreth reports a relationship with National Institutes of Health that includes: funding grants. Dr. Kristiina Rannikmae reports a relationship with UK Biobank that includes: employment. Dr. Cathie Sudlow reports a relationship with UK Biobank that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
This research has been conducted using the UK Biobank Resource under Application Number 100584.
Footnotes
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ajpc.2025.101055.
Appendix. Supplementary materials
References
- 1.Bhatia H.S., Wilkinson M.J. Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies. J Clin Med. 2022;11 doi: 10.3390/jcm11206040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bhatia H.S .WM. Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies. J Clin Med. 2022:6040. doi: 10.3390/jcm11206040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Björnson E., Adiels M., Taskinen M.R., et al. Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis. J Am Coll Cardiol. 2024;83:385–395. doi: 10.1016/j.jacc.2023.10.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Grundy S.M., Stone N.J., Bailey A.L., et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018;73:e285–e350. doi: 10.1016/j.jacc.2018.11.003. 2019. [DOI] [PubMed] [Google Scholar]
- 5.Koschinsky M.L., Bajaj A., Boffa M.B., et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18:e308–e319. doi: 10.1016/j.jacl.2024.03.001. [DOI] [PubMed] [Google Scholar]
- 6.Bhatia H.S., Trainor P., Carlisle S., et al. Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2024;13 doi: 10.1161/JAHA.123.033562. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Huang Y., Zhang R., Han L., et al. Lipoprotein(a) and stroke: a two-sample mendelian randomization study. Front Aging Neurosci. 2023;15 doi: 10.3389/fnagi.2023.1178079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wang S., Zha L., Chen J., et al. The relationship between lipoprotein(a) and risk of cardiovascular disease: a mendelian randomization analysis. Eur J Med Res. 2022;27:211. doi: 10.1186/s40001-022-00825-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Arora P., Kalra R., Callas P.W., et al. Lipoprotein(a) and risk of ischemic stroke in the REGARDS study. Arter Thromb Vasc Biol. 2019;39:810–818. doi: 10.1161/ATVBAHA.118.311857. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Nave A.H., Lange K.S., Leonards C.O., et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242:496–503. doi: 10.1016/j.atherosclerosis.2015.08.021. [DOI] [PubMed] [Google Scholar]
- 11.Virani S.S., Brautbar A., Davis B.C., et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis risk in communities (ARIC) Study. Circulation. 2012;125:241–249. doi: 10.1161/CIRCULATIONAHA.111.045120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Arnold M., Schweizer J., Nakas C.T., et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. Eur Heart J. 2021;42:2186–2196. doi: 10.1093/eurheartj/ehab081. [DOI] [PubMed] [Google Scholar]
- 13.Ohira T., Schreiner P.J., Morrisett J.D., Chambless L.E., Rosamond W.D., Folsom A.R. Lipoprotein(a) and incident ischemic stroke: the atherosclerosis risk in communities (ARIC) study. Stroke. 2006;37:1407–1412. doi: 10.1161/01.STR.0000222666.21482.b6. [DOI] [PubMed] [Google Scholar]
- 14.Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853. doi: 10.1093/eurheartj/ehq386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Bhatia H.S., Becker R.C., Leibundgut G., et al. Lipoprotein(a), platelet function and cardiovascular disease. Nat Rev Cardiol. 2024;21:299–311. doi: 10.1038/s41569-023-00947-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kumar P., Swarnkar P., Misra S., Nath M. Lipoprotein (a) level as a risk factor for stroke and its subtype: a systematic review and meta-analysis. Sci Rep. 2021;11 doi: 10.1038/s41598-021-95141-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Fu H., Zhang D., Zhu R., et al. Association between lipoprotein(a) concentration and the risk of stroke in the Chinese Han population: a retrospective case-control study. Ann Transl Med. 2020;8:212. doi: 10.21037/atm.2020.01.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Ishikawa S., Kotani K., Kario K., et al. Inverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population. Thromb Res. 2013;131:e54–e58. doi: 10.1016/j.thromres.2012.11.032. [DOI] [PubMed] [Google Scholar]
- 19.Ariyo A.A., Thach C., Tracy R. Cardiovascular Health Study I. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108–2115. doi: 10.1056/NEJMoa001066. [DOI] [PubMed] [Google Scholar]
- 20.Sudlow C., Gallacher J., Allen N., et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12 doi: 10.1371/journal.pmed.1001779. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Cohn E.G., Hamilton N., Larson E.L., Williams J.K. Self-reported race and ethnicity of US biobank participants compared to the US Census. J Community Genet. 2017;8:229–238. doi: 10.1007/s12687-017-0308-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Patel A.P., Wang M., Pirruccello J.P., et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arter Thromb Vasc Biol. 2021;41:465–474. doi: 10.1161/ATVBAHA.120.315291. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Nguyen T.T., Ellefson R.D., Hodge D.O., Bailey K.R., Kottke T.E., HS Abu-Lebdeh. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997;96:1390–1397. doi: 10.1161/01.cir.96.5.1390. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.


